Cyclosporine and prednisolone combination therapy as a potential therapeutic strategy for relentless placoid chorioretinitis

Takehiko Urakia, Kenichi Nambaa,∗, Kazuomi Mizuuchia, Daiju Iwataa, Shigeaki Ohnoa, Nobuyoshi Kitaiib, Susumu Ishidaa

aDepartment of Ophthalmology, Faculty of Medicine and Graduate School of Medicine, Hokkaido University, Sapporo, Japan
bDepartment of Ophthalmology, Health Sciences University of Hokkaido, Sapporo, Japan

ARTICLE INFO

Keywords:
Relentless placoid chorioretinitis
APMPPE
Serpiginous choroiditis
Cyclosporine
Prednisolone

ABSTRACT

Purpose: Relentless placoid chorioretinitis (RPC) is a new disease concept that was proposed by Jones et al. in 2000. Some cases of RPC have been reported; however, a treatment strategy has not yet been established. We report herein four cases of patients diagnosed with RPC.

Observations: We experienced four cases of RPC in patients aged 24–51 years. All patients exhibited retinal lesions similar to that seen in acute posterior multifocal placoid pigment epitheliopathy or serpiginous choroiditis from the posterior pole to the surrounding region. Although patients underwent systemic prednisolone (PSL) therapy, recurrence was observed and the retinal scar formation was progressive; they were then diagnosed with RPC. In all cases, cyclosporine (CyA) was administered in addition to PSL, no recurrence was observed thereafter.

Conclusions and Importance: RPC is a rare disease, and a treatment strategy has not yet been established. CyA and PSL combination therapy is considered to be effective in the treatment of RPC.

1. Introduction

Relentless placoid chorioretinitis (RPC) is a new clinical entity that was proposed by Jones BE et al. in 2000.1 RPC exhibits fundus and fluorescein angiography findings similar to acute posterior multifocal placoid pigment epitheliopathy (APMPPE) or serpiginous choroiditis (SC); however, its clinical manifestations differ in the following ways: 1) multifocal retinal activity results in the appearance of numerous (>50) lesions, 2) lesions are widespread anterior and posterior to the equator of the fundus, 3) healed lesions involve the superficial choroid, and 4) the clinical course is prolonged with recurrences months to years after initial onset.1 The term ampiginous choroiditis has been used to describe the conditions of such patients.2

The treatment strategy for RPC has not yet been established. Thus far, some cases of RPC have been reported,1,3-12 most of which were refractory to prednisolone (PSL) administration and were recurrent. Only a few cases were reported as treated with cyclosporine (CyA)1 or mycophenolate mofetil,6 and the efficacy of these treatments is not known. Herein, we report four cases in which patients were diagnosed with RPC, and cyclosporine and prednisolone combination therapy was considered to be effective.

The study was a retrospective observational study and was approved by the ethics committee of Hokkaido University Hospital (approval number 015-0327) and carried out in accordance with the Declaration of Helsinki and Ethical Guideline for Clinical Studies stipulated by the Ministry of Health, Labor and Welfare, Japan.

2. Findings

2.1. Case 1

A 29-year-old man weighing 87.6 kg and suffering for 1 week from slight occipital headaches, blurred vision, and hyperemia in his right eye (OD) visited our hospital. The patient had no significant past medical history or drug allergies, and had no significant travel history. At the initial visit, best-corrected visual acuity (BCVA) was 0.2 OD and 1.2 in his left eye (OS). Slit-lamp examination showed trace flare and 2+ cells in the anterior chamber (AC) with keratic precipitates and anterior vireous cells OD, whereas no inflammatory findings were seen OS in the anterior segment.

Funduscopic examination showed numerous placoid lesions that appeared to be mixed with fresh and old scar lesions in both eyes (OU).

* Corresponding author. Department of Ophthalmology, Faculty of Medicine and Graduate School of Medicine, Hokkaido University, N15-W7, Kita-ku, Sapporo 060-8638, Japan.
E-mail address: knamba@med.hokudai.ac.jp (K. Namba).

https://doi.org/10.1016/j.ajoc.2019.03.005
Received 9 August 2018; Received in revised form 6 February 2019; Accepted 18 March 2019
Available online 23 March 2019
2451-9936/ © 2019 The Authors. Published by Elsevier Inc. This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/BY-NC-ND/4.0/).

A 24-year-old man weighing 56 kg complained of blurred vision OU starting 4 days before his initial visit to our hospital. The patient had no significant past medical history or drug allergies, and had no significant travel history. At the initial visit, BCVA was found to be 0.3 OD and 0.1 OS. Slit-lamp examination demonstrated a clear AC. Funduscopic examination revealed scattered white placoid lesions, which seemed to be fresh, from the posterior pole to the peripheral fundus with numerous scattered scar lesions OU (Fig. 3). No obvious vitreous opacity was seen OU.

FA revealed early hypofluorescence, followed by late hyperfluorescence consistent with the white lesions and hypofluorescence that was consistent with scar lesions. ICGA showed hypofluorescent dark areas from early to late phase. OCT revealed indistinct EZ and IDZ, which were consistent with the white placoid lesions, and the presence of a slight serous retinal detachment. The examination of cerebrospinal fluid showed slight pleocytosis (7 cells/μl). Blood examinations including syphilis lipid antigen (rapid plasma reagin; RPR) and treponema antigen (treponema pallidum Latex immuno Assay; TPLA) and QuantiFERON-TB Gold® were all negative.

RPC was considered in this case because of the numerous lesions that had spread widely from the posterior pole to the anterior retina. Because of the marked decrease in BCVA OU, steroid pulse therapy (3 days of 1000 mg/day methylprednisolone, followed by 60 mg/day PSL) was administered. Two weeks after the initial presentation, funduscopy revealed that placoid fresh lesions had resolved with the remaining scar formations, and BCVA had recovered to 0.9 OD and 0.3 OS. However, a recurrence was observed 3 weeks after the initial presentation when the dose of PSL was 30 mg/day. BCVA was 0.9 OD and 0.6 OS. Although AC was clear and no vitreous opacity was seen, 1+ anterior vitreous cells were observed OS. Fresh retinal lesions were observed in the peripheral fundus OU (with OD being worse than OS). With 40 mg of STTA OD and PSL to 40mg/day, these fresh lesions were resolved with scarring remaining.

Thereafter, during the decreasing dose of PSL, the patient showed the third and the fourth recurrence. The patient demonstrated fresh placoid retinal lesions within 2 months and required an increased dose of PSL each time. Therefore, CyA was initiated at a dose of 200 mg/day in addition to PSL. The patients showed slight recurrences with peripheral retinal exudates OS 8 months later, however, since then, no recurrences with retinal lesions have not been observed for 42 months. Dose of PSL could be reduced and be stopped, and dose of CyA also could be reduced to 125mg/day. Afterward, the patients showed only anterior segment inflammation OS once without posterior segment inflammation. The patient has kept his BCVA at 1.0 OD and 1.2 OS.
2.3. Case 3

A 43-year-old man weighing 85 kg had a history of uveitis showing iridocyclitis and PC scar like choriretinal scar OD 3 years ago, and he showed relapse of iridocyclitis 2 year ago. He visited an eye clinic complained of redness of the eye OS and he was referred to our hospital with the treatment with 0.1% betamethasone eye drop. The patient had no significant past medical history or drug allergies, and had no significant travel history.

At the initial visit, BCVA was 1.2 OU. Slit-lamp examination demonstrated a trace flare & occasional cells OD and 1 + flare & 1 + cells OS in AC. Almost total posterior iris synchiae was seen OD. Funduscopic examination revealed the presence of numerous scattered scar lesions accompanied with fresh white lesions without vitreous opaqueness OU. (Fig. 4a). FA demonstrated early hypofluorescence followed by late hyperfluorescence that was consistent with the white lesions. ICGA showed hypofluorescent dark areas from early to late phase. Blood examinations including RPR, TPLA, and T-SPOT. TB were all negative.

These white lesions were seen in macular area OD, therefore, 40mg of STTA OD was performed, and administration of oral PSL 15mg/day was started. White lesions were resolved with scarring remaining.

Two months later, although he was not aware any changes in vision, new white chorioretinal lesions were seen in addition to old scar lesions OU (Fig. 4b).

Because numerous lesions that had spread widely in the ocular fundus were seen and he showed the recurrence rapidly even with systemic steroid therapy, RPC was considered.

Therefore, 250 mg/day of CyA was administered in addition to 30mg/day of PSL. For the past 8 months, no recurrences have been seen, and dose of PSL and CYA could be reduced to 10 mg/day and 200mg/day respectively. The patient has kept his BCVA at 1.2 OU.

2.4. Case 4

A 51-year-old woman weighing 60 kg complaining of ocular pain and hyperemia OU over a 2-day period visited our hospital. She had no medical history except for sudden hearing loss of her left ear, and had no significant travel history. At the initial visit, BCVA was 0.02 OD and hand motion OS. She showed severe AC inflammation with 3 + cells, hypopyon and fibrin formation along with partial posterior synchiae OU (Fig. 5). Vitreous opaqueness was also observed OU. Numerous white placoid chorioretinal lesions were scattered from the macula to the mid-peripheral fundus OU.

FA demonstrated early hypofluorescence followed by late hyperfluorescence that was consistent with the white lesions. ICGA showed hypofluorescent dark areas from early to late phase. Blood examinations including RPR, TPLA were all negative. The examination of cerebrospinal didn’t show pleocytosis. With 60mg/day of PSL, all inflammatory findings were resolved and most white placoid lesions disappeared OU. BCVA recovered to 1.0 OD and 0.8 OS.

Eight months after the initial presentation, when PSL doses were gradually decreased to 2.5 mg/day, the first recurrence was observed. BCVA was 1.0 OD and 0.5 OS. AC inflammation with 2 + cells were observed OU. Numerous white placoid chorioretinal lesions appeared again in the mid-to-peripheral fundus OU. OCT revealed the presence of serous retinal detachments in the macular area OU. With the dose of PSL increased to 30 mg/day, although scar formations remained, the white placoid chorioretinal lesions were resolved 2 weeks later.

Thereafter, the patient developed several recurrences when the dose of PSL decreased to 2.5–5.0 mg/day; the dose of PSL was increased to 30 mg/day in each recurrence. Consequently, orange color chorioretinal scar lesions were widely spread from the posterior pole to the peripheral retina (Fig. 6).
In addition to the increased PSL dose (20 mg/day), 170 mg/day of CyA was initiated with the seventh recurrence. Since then, recurrences with chorioretinal lesions have not been observed for 44 months whereas 3 times of slight recurrences with anterior chamber cells and vitreous haze were observed in the period. The dose of PSL and CyA could be reduced to 7.5 mg/day and 150 mg/day respectively. The patient has kept her BCVA at 1.2 OU.

3. Results

Recurrences were seen in this series of 4 RPC cases when they were treated with PSL alone. In all cases, after CyA combined with PSL was administered no severe recurrences have been observed for 8–48 months, and the dose of PSL could be reduced.

4. Discussion

All four cases exhibited placoid chorioretinal white lesions scattering from the posterior pole to peripheral retina, and part of them changed to scar lesions similar to those seen in APMPPE or SC; however, because all cases were refractory to steroid therapy alone and showed recurrences resulting in expanding of retinal scar lesions, it is believed that the diagnosis of RPC in these cases were reasonable and proper.

Since Jones et al. proposed the concept of RPC in 2000, a number of cases have been reported1–11; however, the shape of chorioretinal infiltrates and the clinical course differed in each case. Therefore, RPC cannot be truly considered to have been established as a single disease concept.

Pathogenesis of this disease is still not clear. Two of our four cases presented with pleocytosis, indicating the presence of meningitis; however, fundus findings apparently differed from Vogt-Koyanagi-Harada (VKH) disease in which pleocytosis is associated with a high rate, and none of the extraocular findings that accompany VKH disease were observed in the subsequent course. It is possible that some types of viral infections related to the development of meningitis may relate to the onset of RPC. We examined laboratory work up for syphilis and
tuberculosis in every cases, but we did not have the positive result. As there is the term “relentless” in the name of RPC, this disease is difficult to be controlled with PSL alone. In previous reports, some additional medicine has been used in combination with PSL. CyA 100–150 mg/day was started and PSL could be tapered off without any recurrences in two cases. In other cases, mycophenolate mofetil 1000–2000 mg/day was administrated with PSL, and no recurrence was observed for 15–18 months. CyA is a most common T-cell-specific immunosuppressant and has been used for tissue transplantation and for autoimmune diseases all over the world. In this study CyA in combination with PSL was administered in all 4 cases that were refractory to PSL monotherapy, and after starting the combination therapy recurrence has not been observed and dose of PSL could be reduced successfully in all cases. CyA and PSL combination therapy is considered to be a potential therapeutic strategy for RPC. We examined only CyA this time, however, recently the efficacy of biologics including infliximab and adalimumab or other immunosuppressants including micofenolate mofetil for non-inflectious uveitis have been reported, and they may be good candidates as the therapeutic agents for RPC. The examination about them is the subject for future analysis.

5. Conclusions

RPC is a refractory disease to PSL monotherapy. CyA and PSL combination therapy is the considerable treatment for RPC showing recurrences.

6. Patients consent

Institutional review board approved this retrospective case report. Consent to publish the case report was not obtained. This report does not contain any personal information that could lead to the identification of the patient.

Conflicts of Interest

The following authors have no financial disclosures: KU, KN, KM, DI, SO, NK, SI.

7. Authorship

All authors attest that they meet the current ICMJE criteria for Authorship.

Funding

No funding or grant support

Acknowledgements

None.

References

1. Jones BE, Jampol LM, Yannuzzi LA, et al. Relentless placoid chorioretinitis. Arch Ophthalmol. 2000;118(1):931–938.
2. Nussenblatt R, Whitcup SPA. Uveitis: Fundamentals and Clinical Practice. second ed. 1996; 1996.
3. Orihara T, Wakabayashi T, Okada AA, et al. A young Japanese man with relentless placoid chorioretinitis. Jpn J Ophthalmol. 2005;49:539-542.
4. Amer R, Florescu T. Optical coherence tomography in relentless placoid chorioretinitis. Clin Exp Ophthalmol. 2008;36(4):388–390.
5. Chen E. Relentless placoid chorioretinitis. Ophthalmic Surg Lasers Imag. 2008;40:87–88.
6. Yeh S, Lew JC, Wong WT, Nussenblatt RB. Relentless placoid chorioretinitis associated with central nervous system lesions treated with mycophenolate mofetil. Arch Ophthalmol. 2009;127:341–343.
7. Jyotirmay B, Jafferji SS, Sudharshan S, et al. Clinical profile, treatment, and visual outcome of ampiginous choroiditis. Ocul Immunol Inflamm. 2010;18(1):46-51.
8. Khalifa YM, Monahan PM, Acharya NR. Ampiginous choroiditis following quadivalent human papilloma virus vaccine. Br J Ophthalmol. 2010;94(1):137-139.
9. Bhuibhar SS, Biswas J. Nested PCR positive tubercular ampiginous choroiditis: a case report. Ocul Immunol Inflamm. 2012;20(4):303–305.
10. Mirza R. Relentless placoid chorioretinitis. Int Ophthalmol Clin. 2012;52:237–242.
11. Patel M, Vavvas DG. Fundus autofluorescence in ampiginous choroiditis. Ophthalmic Surg Lasers Imaging Retina. 2013;44(4):393–397.
12. Veronese C, Marcheggiani EB, Tassi F, et al. Early autofluorescence findings of relentless placoid chorioretinitis. Retina. 2014;34(3):625–627.